Nasal Septum Perforation: a Side Effect of Bevacizumab Chemotherapy in Breast Cancer Patients

Overview

Journal Br J Cancer

Specialty Oncology

Date 2010 Aug 26

PMID 20736943

Citations 17

Authors

A Mailliez

C Baldini

J T Van

V Servent

Y Mallet

J Bonneterre

Affiliations

Soon will be listed here.

Abstract

Background: Bevacizumab is an anti-vascular endothelial growth factor approved in association with paclitaxel or docetaxel as first line in patients (pts) with metastatic breast cancer. Rare cases of nasal septum perforations have been reported. We report our experience of nasal perforation in breast cancer pts receiving bevacizumab and chemotherapy either in the adjuvant or in the metastatic settings.

Methods: Between 1 January and 31 December 2009, 70 pts received bevacizumab together with chemotherapy. All the pts who had received bevacizumab were referred to the ENT specialist. Symptoms potentially related were looked for. Side effects were graded according to CTCAE.

Results: Five nasal septum perforations were diagnosed (5 out of 70; 7.14%). Bevacizumab dose was 15 mg kg(-1) 3 weekly. Three pts were metastatic. Bevacizumab was associated with docetaxel (100 mg m(-2) every 3 weeks) in two pts and with weekly paclitaxel in one. The last two pts received bevacizumab in combination with anthracyclin and then taxanes in the adjuvant setting. In these two cases, nasal septum perforation occurred at the time of docetaxel treatment.

Conclusion: A high incidence of nasal septum perforation has been shown in pts with breast cancer receiving bevacizumab together with chemotherapy. Several mechanisms could be involved (mucositis, delayed tissue repair, antiangiogenic action of taxanes).

Citing Articles

Progress in Nanotechnology for Treating Ocular Surface Chemical Injuries: Reflecting on Advances in Ophthalmology.

Qi Q, Su D, Zhuang S, Yao S, Heindl L, Fan X Adv Sci (Weinh). 2025; 12(6):e2407340.

PMID: 39755928 PMC: 11809354. DOI: 10.1002/advs.202407340.

Five years of safety profile of bevacizumab: an analysis of real-world pharmacovigilance and randomized clinical trials.

Wang L, Fei Y, Qu H, Zhang H, Wang Y, Wu Z J Pharm Health Care Sci. 2024; 10(1):1.

PMID: 38167326 PMC: 10763108. DOI: 10.1186/s40780-023-00314-w.

Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type.

Subhan M, Parveen F, Shah H, Yalamarty S, Ataide J, Torchilin V Cancers (Basel). 2023; 15(8).

PMID: 37190133 PMC: 10137302. DOI: 10.3390/cancers15082204.

Perforation of the Nasal Septum in a Colorectal Cancer Patient Treated With Aflibercept: A Case Report.

Benitez Fuentes J, Lopez de Sa Lorenzo A, Calvo Elias A, Toledano Rojas C, Granja Ortega M Cureus. 2022; 14(7):e26780.

PMID: 35836714 PMC: 9275094. DOI: 10.7759/cureus.26780.

FA2H Exhibits Tumor Suppressive Roles on Breast Cancers via Cancer Stemness Control.

Dai X, Zhang S, Cheng H, Cai D, Chen X, Huang Z Front Oncol. 2019; 9:1089.

PMID: 31709178 PMC: 6821679. DOI: 10.3389/fonc.2019.01089.

References

Tan T, Stevenson B, Yip D . Docetaxel-induced nasal septal perforation. Intern Med J. 2006; 36(7):471-2. DOI: 10.1111/j.1445-5994.2006.01105.x. View

Pinto Marin A, Redondo Sanchez A, Arranz E . Nasal septum perforation in a breast cancer patient treated with bevacizumab. Ann Oncol. 2009; 20(11):1901-2. DOI: 10.1093/annonc/mdp451. View

Ferrara N, Alitalo K . Clinical applications of angiogenic growth factors and their inhibitors. Nat Med. 1999; 5(12):1359-64. DOI: 10.1038/70928. View

Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez E . Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007; 357(26):2666-76. DOI: 10.1056/NEJMoa072113. View

Belotti D, Vergani V, Drudis T, Borsotti P, Pitelli M, Viale G . The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin Cancer Res. 1996; 2(11):1843-9. View

Vignes S, Chaillet M, Cabane J, Piette J . [Nasal septal perforation and systemic disease]. Rev Med Interne. 2002; 23(11):919-26. DOI: 10.1016/s0248-8663(02)00711-7. View

Power D, Kemeny N . Nasal septum perforation and bevacizumab. Med Oncol. 2010; 28(1):89-93. DOI: 10.1007/s12032-010-9464-9. View

Fakih M, Lombardo J . Bevacizumab-induced nasal septum perforation. Oncologist. 2006; 11(1):85-6. DOI: 10.1634/theoncologist.11-1-85. View

Hotchkiss K, Ashton A, Mahmood R, Russell R, Sparano J, Schwartz E . Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002; 1(13):1191-200. View

10.

Burkart C, Grisel J, Hom D . Spontaneous nasal septal perforation with antiangiogenic bevacizumab therapy. Laryngoscope. 2008; 118(9):1539-41. DOI: 10.1097/MLG.0b013e31817c4296. View

11.

Traina T, Norton L, Drucker K, Singh B . Nasal septum perforation in a bevacizumab-treated patient with metastatic breast cancer. Oncologist. 2006; 11(10):1070-1. DOI: 10.1634/theoncologist.11-10-1070. View

12.

Grant D, Williams T, Zahaczewsky M, Dicker A . Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 2003; 104(1):121-9. DOI: 10.1002/ijc.10907. View

13.

Ruiz N, Fernandez-Martos C, Romero I, Pla A, Maiquez J, Calatrava A . Invasive fungal infection and nasal septum perforation with bevacizumab-based therapy in advanced colon cancer. J Clin Oncol. 2007; 25(22):3376-7. DOI: 10.1200/JCO.2007.12.0006. View

14.

Plate K, Breier G, Weich H, Risau W . Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature. 1992; 359(6398):845-8. DOI: 10.1038/359845a0. View

15.

Younger R, Blokmanis A . Nasal septal perforations. J Otolaryngol. 1985; 14(2):125-31. View

16.

Siau K, Varughese M . Thrombotic microangiopathy following docetaxel and trastuzumab chemotherapy: a case report. Med Oncol. 2009; 27(4):1057-9. DOI: 10.1007/s12032-009-9333-6. View